Literature DB >> 17436223

Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women.

Audrey L French1, Eva Operskalski, Marion Peters, Howard D Strickler, Phyllis C Tien, Gerald B Sharp, Marshall J Glesby, Mary Young, Michael Augenbraun, Eric Seaberg, Andrea Kovacs.   

Abstract

To characterize predictors of isolated hepatitis B core antibody (anti-HBc) among human immunodeficiency virus (HIV)-infected and HIV-uninfected women, we compared 702 women with anti-HBc and hepatitis B surface antibody (anti-HBs) with 490 women with isolated anti-HBc (1.8% of whom had detectable hepatitis B virus [HBV] DNA). Factors independently associated with isolated anti-HBc without viremia were detectable hepatitis C virus (HCV) RNA, HIV positivity, history of injection drug use, >10 lifetime sex partners, and HIV RNA level >100,000 copies/mL. Anti-HBs levels were lower among anti-HCV-positive women. Isolated anti-HBc was rarely explained by occult HBV in this cohort but may be explained by the influence of viral coinfections on anti-HBs level or durability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17436223      PMCID: PMC3133731          DOI: 10.1086/515578

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

Authors:  C Bréchot; V Thiers; D Kremsdorf; B Nalpas; S Pol; P Paterlini-Bréchot
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

2.  Isolated antibody to hepatitis B core is associated with hepatitis C virus co-infection.

Authors:  G Greub; P C Frei
Journal:  Clin Microbiol Infect       Date:  2000-11       Impact factor: 8.067

3.  Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.

Authors:  Antje Knöll; Arndt Hartmann; Harald Hamoshi; Karin Weislmaier; Wolfgang Jilg
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

4.  Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.

Authors:  M Wiedmann; U G Liebert; U Oesen; H Porst; M Wiese; S Schroeder; U Halm; J Mössner; F Berr
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study.

Authors:  Vincent Leroy; Marc Bourliere; Magali Durand; Armand Abergel; Albert Tran; Maryline Baud; Danielle Botta-Fridlund; André Gerolami; Denis Ouzan; Philippe Halfon; Jean-Pierre Zarski
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-05       Impact factor: 2.566

6.  Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection.

Authors:  S Auffermann-Gretzinger; E B Keeffe; S Levy
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.

Authors:  Susan Moir; Kisani M Ogwaro; Angela Malaspina; Joshua Vasquez; Eileen T Donoghue; Claire W Hallahan; Shuying Liu; Linda A Ehler; Marie A Planta; Shyamasundaran Kottilil; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

8.  Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication.

Authors:  H Wedemeyer; M Cornberg; B Tegtmeyer; H Frank; H L Tillmann; M P Manns
Journal:  Clin Microbiol Infect       Date:  2004-01       Impact factor: 8.067

9.  Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen.

Authors:  Rajesh T Gandhi; Alysse Wurcel; Barbara McGovern; Hang Lee; Janet Shopis; Colleen P Corcoran; Sarah Toner; Christina Giachetti; Janel Dockter; Paul E Sax; Chinweike Ukomadu
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

10.  Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals.

Authors:  Rajesh T Gandhi; Alysse Wurcel; Hang Lee; Barbara McGovern; Melinda Boczanowski; Roslyn Gerwin; Colleen P Corcoran; Zbigniew Szczepiorkowski; Sarah Toner; Daniel E Cohen; Paul E Sax; Chinweike Ukomadu
Journal:  Clin Infect Dis       Date:  2003-06-06       Impact factor: 9.079

View more
  11 in total

1.  Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.

Authors:  Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

Review 2.  Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.

Authors:  Jennifer J Chang; Neaka Mohtashemi; Debika Bhattacharya
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

3.  Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Authors:  Stefan Reuter; Mark Oette; Frank Clemens Wilhelm; Bastian Beggel; Rolf Kaiser; Melanie Balduin; Finja Schweitzer; Jens Verheyen; Ortwin Adams; Thomas Lengauer; Gerd Fätkenheuer; Herbert Pfister; Dieter Häussinger
Journal:  Med Microbiol Immunol       Date:  2010-09-19       Impact factor: 3.402

4.  Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052.

Authors:  Amy E Greer; San-San Ou; Ethan Wilson; Estelle Piwowar-Manning; Michael S Forman; Marybeth McCauley; Theresa Gamble; Cholticha Ruangyuttikarn; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; Mulinda Nyirenda; Beatriz Grinsztejn; Jose Henrique Pilotto; Natthapol Kosashunhanan; Marineide Gonçalves de Melo; Joseph Makhema; Victor Akelo; Ravindre Panchia; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman; Chloe L Thio; Alexandra Valsamakis
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

5.  Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study.

Authors:  Mallory D Witt; Roger J Lewis; Gunter Rieg; Eric C Seaberg; Charles R Rinaldo; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

6.  Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women.

Authors:  Woottichai Khamduang; Nicole Ngo-Giang-Huong; Catherine Gaudy-Graffin; Gonzague Jourdain; Weerapong Suwankornsakul; Tapnarong Jarupanich; Veeradate Chalermpolprapa; Sirisak Nanta; Noossara Puarattana-Aroonkorn; Sakchai Tonmat; Marc Lallemant; Alain Goudeau; Wasna Sirirungsi
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania.

Authors:  Florida J Muro; Suzanne P Fiorillo; Philoteus Sakasaka; Christopher Odhiambo; Elizabeth A Reddy; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-04-12       Impact factor: 3.164

8.  Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.

Authors:  Audrey L French; Michael Y Lin; Charlesnika T Evans; Lorie Benning; Marshall J Glesby; Mary A Young; Eva A Operskalski; Michael Augenbraun; Marion Peters
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

9.  Low rates of hepatitis B virus screening at the onset of chemotherapy.

Authors:  Jessica P Hwang; Michael J Fisch; Hong Zhang; Michael A Kallen; Mark J Routbort; Lincy S Lal; John M Vierling; Maria E Suarez-Almazor
Journal:  J Oncol Pract       Date:  2012-06-12       Impact factor: 3.840

10.  Will a quadruple multiplexed point-of-care screening strategy for HIV-related co-infections be feasible and impact detection of new co-infections in at-risk populations? Results from cross-sectional studies.

Authors:  Nitika Pant Pai; Rachita Dhurat; Martin Potter; Tarannum Behlim; Geneviève Landry; Caroline Vadnais; Camilla Rodrigues; Lawrence Joseph; Anjali Shetty
Journal:  BMJ Open       Date:  2014-12-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.